{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:46:31Z","timestamp":1794620791429,"version":"4.9.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["U01DP006745-01"],"award-info":[{"award-number":["U01DP006745-01"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009560","name":"American Gastroenterological Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["R01DK13593701A1"],"award-info":[{"award-number":["R01DK13593701A1"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["K23DK129762"],"award-info":[{"award-number":["K23DK129762"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["R01 DK127171"],"award-info":[{"award-number":["R01 DK127171"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011684","name":"Crohn's and Colitis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1053\/j.gastro.2024.07.046","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T18:53:47Z","timestamp":1729277627000},"page":"1460-1482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis"],"prefix":"10.1053","volume":"167","author":[{"given":"Ashwin N.","family":"Ananthakrishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Hassan","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank I.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Haydek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berkeley N.","family":"Limketkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2024.07.046_bib1","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.07.046_bib2","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/ecco-jcc\/jjz003","article-title":"The evolution of health care utilisation and costs for inflammatory bowel disease over ten years","volume":"13","author":"Pillai","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.07.046_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cgh.2017.06.016","article-title":"Natural history of adult ulcerative colitis in population-based cohorts: a systematic review","volume":"16","author":"Fumery","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.07.046_bib4","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.07.046_bib5","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(24)00910-7","article-title":"The efficacy and safety of guselkumab as maintenance therapy in patients with moderate to severely active ulcerative colitis: results from the phase 3 Quasar Maintenance study","volume":"166","author":"Rubin","year":"2024","journal-title":"Gastroenterol"},{"key":"10.1053\/j.gastro.2024.07.046_bib6","first-page":"26","article-title":"Risankizumab induction therapy in patients with moderately to severely active ulcerative colitis: efficacy and safety in the randomized phase 3 INSPIRE study","volume":"11","author":"Louis","year":"2023","journal-title":"United European Gastroenterol J"},{"key":"10.1053\/j.gastro.2024.07.046_bib7","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.07.046_bib8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.07.046_bib9","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.07.046_bib10","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1053\/j.gastro.2020.01.007","article-title":"AGA Technical review on the management of moderate to severe ulcerative colitis","volume":"158","author":"Singh","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.07.046_bib11","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.07.046_bib12","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1136\/gutjnl-2021-326390","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","volume":"71","author":"Burr","year":"2022","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.07.046_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.07.046_bib14","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.07.046_bib15","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.07.046_bib16","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.07.046_bib17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2024.07.046_bib18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"10.1053\/j.gastro.2024.07.046_bib19","first-page":"1","article-title":"netmeta: An R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J\u00a0Stat Softw"},{"key":"10.1053\/j.gastro.2024.07.046_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/flgastro-2023-102559","article-title":"Maintaining remission in Crohn\u2019s disease post surgery: what can we learn from Cochrane?","volume":"15","author":"Gordon","year":"2024","journal-title":"Frontline Gastroenterol"},{"key":"10.1053\/j.gastro.2024.07.046_bib21","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis [published correction appears in N Engl J Med 2006;354:2200]","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.07.046_bib22","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/MCG.0000000000000319","article-title":"Low-dose infliximab for induction and maintenance treatment in Chinese patients with moderate to severe active ulcerative colitis","volume":"49","author":"Jiang","year":"2015","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2024.07.046_bib24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00535-015-1102-z","article-title":"First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis","volume":"51","author":"Kobayashi","year":"2016","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1053\/j.gastro.2024.07.046_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(21)00338-1","article-title":"Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials","volume":"7","author":"Rubin","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.07.046_bib26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00535-013-0922-y","article-title":"Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis","volume":"49","author":"Suzuki","year":"2014","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1053\/j.gastro.2024.07.046_bib27","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2024.07.046_bib28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.07.046_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.07.046_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.07.046_bib31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.07.046_bib32","article-title":"Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study","volume":"14","author":"Motoya","year":"2019","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2024.07.046_bib33","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.07.046_bib34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.07.046_bib35","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study","volume":"165","author":"Peyrin-Biroulet","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.07.046_bib36","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.07.046_bib37","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.07.046_bib38","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.07.046_bib39","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.07.046_bib40","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.07.046_bib41","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.07.046_bib42","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.07.046_bib43","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2024.07.046_bib44","doi-asserted-by":"crossref","first-page":"i623","DOI":"10.1093\/ecco-jcc\/jjac190.0622","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: a phase 3, randomized, placebo-controlled study: results of the LIBERTY-UC study","volume":"17","author":"Sands","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2024.07.046_bib45","article-title":"Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis","volume":"5","author":"Panaccione","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"10.1053\/j.gastro.2024.07.046_bib46","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.cgh.2023.03.040","article-title":"Massachusetts General Hospital Crohn\u2019s And Colitis Center Collaborators. Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: real-world data","volume":"21","author":"Boneschansker","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.07.046_bib47","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib is effective and safe in both ulcerative colitis and Crohn\u2019s disease: prospective real-world experience","volume":"21","author":"Friedberg","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.07.046_bib48","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2024.07.046_bib49","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/ibd\/izaa289","article-title":"Tofacitinib treatment safety in moderate to severe ulcerative colitis: comparison of observational population cohort data from the IBM MarketScan(R) Administrative Claims Database with tofacitinib trial data","volume":"27","author":"Curtis","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2024.07.046_bib50","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1007\/s10620-022-07404-z","article-title":"Comparative risk of thrombotic and cardiovascular events with tofacitinib and anti-TNF agents in patients with inflammatory bowel diseases","volume":"67","author":"Kochar","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2024.07.046_bib51","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme","volume":"50","author":"Sandborn","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.07.046_bib52","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cgh.2023.09.033","article-title":"Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis","volume":"2","author":"Mattay","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.07.046_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227914","article-title":"Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe","volume":"15","author":"Armuzzi","year":"2020","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2024.07.046_bib54","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.14309\/01.ajg.0000776304.52681.bf","article-title":"Impact of prior biologic exposure on patient response to ozanimod for moderate-to-severe ulcerative colitis in the phase 3 True North Study","volume":"116","author":"Sands","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2024.07.046_bib55","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0000000000000754","article-title":"Comparative effectiveness of infliximab and adalimumab in Crohn\u2019s disease and ulcerative colitis","volume":"22","author":"Ananthakrishnan","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2024.07.046_bib56","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/apt.13580","article-title":"Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis","volume":"43","author":"Singh","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.07.046_bib57","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1053\/j.gastro.2022.02.033","article-title":"Higher vs standard adalimumab induction and maintenance dosing regimens for treatment of ulcerative colitis: SERENE UC trial results","volume":"162","author":"Panes","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.07.046_bib58","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus Kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1053\/j.gastro.2024.07.046_bib59","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1053\/j.gastro.2022.09.011","article-title":"Is selectivity the JAKpot winner for inflammatory bowel disease treatment?","volume":"163","author":"D\u2019Amico","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2024.07.046_bib60","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/apt.17305","article-title":"Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent","volume":"57","author":"Buisson","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.07.046_bib61","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cgh.2022.04.038","article-title":"Superior effectiveness of tofacitinib compared to vedolizumab in anti-TNF-experienced ulcerative colitis patients: a nationwide Dutch registry study","volume":"21","author":"Straatmijer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.07.046_bib62","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/ibd\/izad115","article-title":"Real-world evidence comparing tofacitinib and vedolizumab in anti-TNF-experienced patients with ulcerative colitis","volume":"30","author":"Adimadhyam","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2024.07.046_bib63","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231159452","article-title":"Is there an optimal sequence of biologic therapies for inflammatory bowel disease?","volume":"16","author":"Bressler","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1053\/j.gastro.2024.07.046_bib64","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/apt.17816","article-title":"Efficacy and safety of upadacitinib for 16-week extended induction and 52\u2013week maintenance therapy in patients with moderately to severely active ulcerative colitis","volume":"59","author":"Panaccione","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2024.07.046_bib65","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.cgh.2020.10.038","article-title":"Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2024.07.046_bib66","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","article-title":"Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"21","author":"Solitano","year":"2023","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508524054805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508524054805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:54:13Z","timestamp":1778648053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508524054805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0016508524054805"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2024.07.046","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2024.07.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the AGA Institute.","name":"copyright","label":"Copyright"}]}}